IMU Biosciences Series A

IMU Biosciences has secured over $53 million in an oversubscribed Series A funding round, co-led by IQ Capital and Molten Ventures. This marks the company's first major institutional financing. The funds will be used to further develop IMU's proprietary immune dataset, which the company states is the world's largest, and to advance its diagnostic and therapeutic pipeline.